Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities
  • Reading time:5 min(s) read

Berkeley Lights, Inc. (Nasdaq: BLI), a frontrunner in digital cell biology, and Curia, previously AMRI, a number one contract analysis, improvement and manufacturing group (CDMO), immediately introduced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to speed up and develop its antibody-based drug discovery capabilities.

The Beacon system workflow at Curia leverages its proprietary Pentamice® platform, CHO-GSN℠ and TunaCHO℠ platforms, in addition to the corporate’s antibody and cell-line engineering methods. The Pentamice® platform, CHO-GSN℠ and TunaCHO℠ platforms had been developed at LakePharma, which Curia acquired in 2021. Learn extra at curiaglobal.com/beacon.

With the addition of the Beacon system, Curia is ready to present a seamless and complete portfolio of state-of-the-art applied sciences and expertise for speedy development of shopper antibody applications. Its options deal with the earliest stage of discovery, by maturation and improvement, to fabricate of drug substance and closing drug merchandise underneath GMP.

Speed counts in drug discovery, so the power to conduct high-throughput, single-cell experiments is a sport changer, enabling ample and various leads,” mentioned Christopher Conway, president, R&D, Curia. “Advanced technologies such as the Berkeley Lights platform are revolutionizing antibody discovery, tackling key pain points that confront innovators, such as long timelines and limited number of sequences. Our demonstrated ability to integrate technologies, process and scientific expertise ultimately enables us to accelerate the time to clinic and the advance of life-changing life science.” 

Curia scientists evaluated a wide range of applied sciences and chosen the Beacon system primarily based on its confirmed capabilities and seamless integration in Curia’s end-to-end manufacturing worth chain. With its talents to ship towards a spread of targets that fail with conventional applied sciences, mixed with the confirmed immunological variety inherent in its PentaMice® platform, Curia expects to ship distinctive and various antibody sequences with complete knowledge evaluation underneath timelines which might be weeks in length relatively than months, and improvement candidates in six months or fewer.

We are excited to accomplice with Curia, a number one CDMO, of their adoption of the Berkeley Lights platform for antibody discovery. They can now speed up the timeline during which important therapeutics could make it to the clinic,” mentioned Eric Hobbs, Ph.D., president of Antibody Therapeutics at Berkeley Lights. “Curia is showing their commitment to adopting cutting-edge technologies that more rapidly and effectively find the best cells, especially for hard-to-identify antibodies.”

About Curia


Curia, previously AMRI, is a number one contract analysis, improvement and manufacturing group offering services from R&D by industrial manufacturing to pharmaceutical and biopharmaceutical prospects. Curia’s 3,700 staff at 29 places throughout the U.S., Europe and Asia assist its prospects advance from curiosity to remedy. Learn extra at CuriaInternational.com.

About Berkeley Lights


Berkeley Lights is a number one digital cell biology firm targeted on enabling and accelerating the speedy improvement and commercialization of biotherapeutics and different cell-based merchandise for our prospects. The Berkeley Lights Platform captures deep phenotypic, purposeful and genotypic data for hundreds of single cells in parallel and may also ship the dwell biology prospects need within the type of one of the best cells. Our platform is a completely built-in, end-to-end resolution, comprising proprietary consumables, together with our OptoSelect™ chips and reagent kits, superior automation methods, and software software program. We developed the Berkeley Lights Platform to supply essentially the most superior atmosphere for speedy purposeful characterization of single cells at scale, the purpose of which is to ascertain an business normal for our prospects all through their cell-based product worth chain.

Berkeley Lights’ Beacon® and Lightning™ methods and Culture Station™ instrument are FOR RESEARCH USE ONLY. Not to be used in diagnostic procedures.

Forward-Looking Statements


To the extent that statements contained on this press launch aren’t descriptions of historic information relating to Berkeley Lights or its merchandise, they’re forward-looking statements reflecting the present beliefs and expectations of administration. Such forward-looking statements contain substantial recognized and unknown dangers and uncertainties that relate to future occasions, and precise outcomes and product efficiency may differ considerably from these expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to replace or revise any forward-looking statements. For an additional description of the dangers and uncertainties referring to the Company’s development and continuous evolution see the statements within the “Risk Factors” sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission. 

Posted in: Business / Finance | Device / Technology News | Miscellaneous News

Tags: Antibodies, Antibody, Antibody Discovery, Automation, Biopharmaceutical, Biotherapeutics, Cell, Cell Biology, Diagnostic, Drug Discovery, Evolution, Life science, Manufacturing, Pain, pH, Research, Therapeutics

Citations

Please use one of many following codecs to quote this text in your essay, paper or report:

  • APA

    Berkeley Lights, Inc. (2022, June 06). Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities. News-Medical. Retrieved on June 06, 2022 from https://www.news-medical.web/information/20220606/Curia-Adopts-the-Berkeley-Lights-Platform-to-Expand-its-Antibody-Discovery-Capabilities.aspx.

  • MLA

    Berkeley Lights, Inc. “Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities”. News-Medical. 06 June 2022. .

  • Chicago

    Berkeley Lights, Inc. “Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities”. News-Medical. https://www.news-medical.web/information/20220606/Curia-Adopts-the-Berkeley-Lights-Platform-to-Expand-its-Antibody-Discovery-Capabilities.aspx. (accessed June 06, 2022).

  • Harvard

    Berkeley Lights, Inc. 2022. Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities. News-Medical, seen 06 June 2022, https://www.news-medical.web/information/20220606/Curia-Adopts-the-Berkeley-Lights-Platform-to-Expand-its-Antibody-Discovery-Capabilities.aspx.

Suggested Reading

If you are interested in working in a distraction free environment, visit our site Blissful Noises where we provide various sounds and features to help you focus or relax.